Clinical utility of fractional exhaled nitric oxide in the management of asthma and COPD

Steve W Turner; Anne B. Chang; Ian A. Yang

doi:10.1183/20734735.0268-2019

Clinical utility of fractional exhaled nitric oxide in the management of asthma and COPD

Steve W Turner^* (Corresponding Author), Anne B. Chang, Ian A. Yang

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

4 Downloads (Pure)

Abstract

Fractional Exhaled Nitric Oxide (F_ENO) values can be easily measured using portable analysers and is a surrogate marker of airway eosinophilia. F_ENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect F_ENO, especially atopy which is associated with elevated F_ENO. One (from the National Institute of Care and Health Excellence, NICE) guideline recommends that F_ENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged over 5 years. The role of F_ENO in monitoring asthma is much less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently F_ENO is not recommended for diagnosis or monitoring of COPD. Although F_ENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of F_ENO as an objective measurement in asthma and COPD can be realised.

Original language	English
Pages (from-to)	306-316
Number of pages	11
Journal	Breathe
Volume	15
Issue number	4
DOIs	https://doi.org/10.1183/20734735.0268-2019
Publication status	Published - 1 Dec 2019

Access to Document

10.1183/20734735.0268-2019Licence: CC BY-NC

Turner_etal_Breathe_Clincical_utility_VOR
Copyright ©ERS 2019 http://creativecommons.org/licenses/by-nc/4.0/ Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Final published version, 284 KBLicence: CC BY-NC

Cite this

@article{c0feb03e299646bbb7adde4bb787194f,

title = "Clinical utility of fractional exhaled nitric oxide in the management of asthma and COPD",

abstract = "Fractional Exhaled Nitric Oxide (FENO) values can be easily measured using portable analysers and is a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy which is associated with elevated FENO. One (from the National Institute of Care and Health Excellence, NICE) guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged over 5 years. The role of FENO in monitoring asthma is much less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.",

author = "Turner, {Steve W} and Chang, {Anne B.} and Yang, {Ian A.}",

note = "Footnotes Conflict of interest: S.W. Turner has received apparatus at no cost from Circassia (and formerly Aerocrine) for measuring nitric oxide in three research studies. Conflict of interest: A.B. Chang reports grants from National Health and Medical Research Council, Australia related to the submitted work (multiple grants relating to cough, bronchiectasis and PBB). Other grants and interests from GSK (member of a data monitoring committee relating to an unlicensed vaccine), Up to Date (author of sections on paediatric cough) and BMJ Evidence Centre (author of two chapters on paediatric asthma with monies received (to Institution)) are outside the submitted work. Conflict of interest: I.A. Yang has nothing to disclose. Copyright {\textcopyright}ERS 2019",

year = "2019",

month = dec,

day = "1",

doi = "10.1183/20734735.0268-2019",

language = "English",

volume = "15",

pages = "306--316",

journal = "Breathe",

issn = "1810-6838",

publisher = "European Respiratory Society",

number = "4",

}

TY - JOUR

T1 - Clinical utility of fractional exhaled nitric oxide in the management of asthma and COPD

AU - Turner, Steve W

AU - Chang, Anne B.

AU - Yang, Ian A.

N1 - Footnotes Conflict of interest: S.W. Turner has received apparatus at no cost from Circassia (and formerly Aerocrine) for measuring nitric oxide in three research studies. Conflict of interest: A.B. Chang reports grants from National Health and Medical Research Council, Australia related to the submitted work (multiple grants relating to cough, bronchiectasis and PBB). Other grants and interests from GSK (member of a data monitoring committee relating to an unlicensed vaccine), Up to Date (author of sections on paediatric cough) and BMJ Evidence Centre (author of two chapters on paediatric asthma with monies received (to Institution)) are outside the submitted work. Conflict of interest: I.A. Yang has nothing to disclose. Copyright ©ERS 2019

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Fractional Exhaled Nitric Oxide (FENO) values can be easily measured using portable analysers and is a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy which is associated with elevated FENO. One (from the National Institute of Care and Health Excellence, NICE) guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged over 5 years. The role of FENO in monitoring asthma is much less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.

AB - Fractional Exhaled Nitric Oxide (FENO) values can be easily measured using portable analysers and is a surrogate marker of airway eosinophilia. FENO may be useful in diagnosing and monitoring conditions characterised by airway eosinophilia, i.e. asthma and possibly COPD. Many factors other than asthma and COPD affect FENO, especially atopy which is associated with elevated FENO. One (from the National Institute of Care and Health Excellence, NICE) guideline recommends that FENO should be used as part of the diagnostic pathway for asthma diagnosis in adults and children aged over 5 years. The role of FENO in monitoring asthma is much less clear, and most guidelines do not recommend its use outside of specialist asthma clinics. Currently FENO is not recommended for diagnosis or monitoring of COPD. Although FENO is starting to find a place in the management of asthma in children and adults, considerably more research is required before the potential of FENO as an objective measurement in asthma and COPD can be realised.

U2 - 10.1183/20734735.0268-2019

DO - 10.1183/20734735.0268-2019

M3 - Article

VL - 15

SP - 306

EP - 316

JO - Breathe

JF - Breathe

SN - 1810-6838

IS - 4

ER -

Clinical utility of fractional exhaled nitric oxide in the management of asthma and COPD

Abstract

Access to Document

Fingerprint

Cite this